The effects of prior beta-blocker therapy on serum C-reactive protein levels after percutaneous coronary intervention

Clinical Cardiology

Volumn 28, Issue 5, 2005, Pages 243-246

  Atar, Ilyas ^a,b   Gülmez, Öykü ^a   Atar, Asli ^a   Bozbas, Hüseyin ^a   Yildirir, Aylin ^a   Özin, Bülent ^a   Korkmaz, Mehmet Emin ^a   Müderrisoglu, Haldun ^a  

^a BASKENT UNIVERSITY   (Turkey)

^b Baskent Universitesi Ankara Hastanesi   (Turkey)

Author keywords

Beta blockers; C reactive protein; Percutaneous coronary intervention

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; METOPROLOL; METOPROLOL TARTRATE;

ADULT; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 18744391956     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960280509     Document Type: Article

References (32)

1. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126
2. Ridker PM, Glynn RJ, Hennekens CH: C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-2011
3. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moyé LA, Goldman S, Flaker GC, Braunwald E: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-844
4. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A: The prognostic value of C-reactive protein and serum amyloid, a protein in severe unstable angina. N Engl J Med 1994;331:417-424
5. Liuzzo G, Buffon A, Biasucci LM, Gallimore JR, Caligiuri G, Vitelli A, Altamura S, Ciliberto G, Rebuzzi AG, Crea F, Pepys MB, Maseri A: Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998;98:2370-2376
6. Bazzino O, Diaz R, Tajer C, Paviotti C, Mele E, Trivi M, Piombo A, Prado AH, Paolasso E: Clinical predictors of in-hospital prognosis in unstable angina: ECLA 3. The ECLA Collaborative Group. Am Heart J 1999;137:322-331
7. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979
8. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-641
9. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB: Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462-466
10. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, Crea F, Maseri A: Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34:1512-1521
11. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, Topol EJ, Ellis SG: Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001;104:992-997
12. Mueller C, Buettner HJ, Hodgson JM, Marsch S, Perruchoud AP, Roskamm H, Neumann FJ: Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002;105:1412-1415
13. Versaci F, Gaspardone A, Tomai F, Crea F, Chiariello L, Gioffre PA: Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol 2000;85:92-95
14. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, Nikfardjam M, Stepan E, Wexberg P, Zorn G, Glogar D, Probst P, Maurer G, Huber K: Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 2000;21:1152-1158
15. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schachinger V, Zeiher AM: Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001;37:839-846
16. Gaspardone A, Crea F, Versaci F, Tomai F, Pellegrino A, Chiariello L, Gioffre PA: Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol 1998;82:515-518
17. Pepys MB: C-reactive protein fifty years on. Lancet 1981;1:653-657
18. Murray DR, Prabhu SD, Chandrasekar B: Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 2000;101:2338-2341
19. Burger A, Benicke M, Deten A, Zimmer HG: Catecholamines stimulate interleukin-6 synthesis in rat cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2001;281:H14-21
20. Doo YC, Kim DM, Oh DJ, Ryu KH, Rhim CY, Lee Y: Effect of beta blockers on expression of interleukin-6 and c-reactive protein in patients with unstable angina pectoris. Am J Cardiol 2001;88:422-424
21. Jenkins NP, Keevil BG, Hutchinson IV, Brooks NH: Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease. Am J Med 2002;112:269-274
22. Beattie MS, Shlipak MG, Liu H, Browner WS, Schiller NB, Whooley MA: C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: Data from the Heart and Soul Study. Circulation 2003;107:245-250
23. Anzai T, Yoshikawa T, Takahashi T, Maekawa Y, Okabe T, Asakura Y, Satoh T, Mitamura H, Ogawa S: Early use of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction. Cardiology 2003;99:47-53
24. Joynt KE, Gattis WA, Hasselblad V, Fuzaylov SY, Serebruany VL, Gurbel PA, Gaulden LH, Felker GM, Whellan DJ, O'Connor CM: Effect of angiotensin- converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. Am J Cardiol 2004;93:783-785
25. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-235
26. Walter DH, Fichtlscherer S, Britten MB, Rosin P, Auch-Schwelk W, Schachinger V, Zeiher AM: Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol 2001;38:2006-2012
27. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, Ellis SG: Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002;105:691-696
28. Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, Anderson JL: Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 2000;36:1774-1780
29. Albert MA, Danielson E, Rifai N, Ridker PM, and the PRINCE Investigators: Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. J Am Med Assoc 2001;286:64-70
30. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr, and the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965
31. Ohtsuka T, Hamada M, Hiasa G, Sasaki O, Suzuki M, Hara Y, Shigematsu Y, Hiwada K: Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001;37:412-417
32. Gullestad L, Ueland T, Brunsvig A, Kjekshus J, Simonsen S, Froland SS, Aukrust P: Effect of metoprolol on cytokine levels in chronic heart failure - a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). Am Heart J 2001;141:418-421